PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026Hepatology1 citations

GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes

View Full Paper
XMXianhua MaoHFHaiwei FanMYM-F Yuen

Key Points

  • This research aims to evaluate the effects of GLP-1 receptor agonist and SGLT-2 inhibitor combination on liver and cardiovascular outcomes in individuals with MASLD and type 2 diabetes.
  • Compared outcomes of GLP-1 receptor agonist-SGLT-2 inhibitor combination versus either agent alone in adults with MASLD and type 2 diabetes.
  • Analysis focused on major adverse liver and cardiovascular events.
  • Combination therapy significantly reduced the risk of major adverse liver and cardiovascular outcomes compared to individual treatments.
  • Specific event rates and statistical significance were not detailed in the abstract.

Abstract

In this study, GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse liver and cardiovascular outcomes compared with either agent alone among patients with MASLD and T2D.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mao et al. (2026) studied this question.

synapsesocial.com/papers/69edad8f4a46254e215b52eehttps://doi.org/10.1097/hep.0000000000001771
Ask AI
Helpful
Bookmark
Share
View Full Paper